News - Dainippon Sumitomo Pharma, Latuda


Popular Filters

EMA/CHMP January meeting highlights

EMA/CHMP January meeting highlights


There were a number of positive, and negative, opinions issued on January 24, following the monthly meeting…

AB ScienceAdempasBayerBemfolaDainippon Sumitomo PharmaEuropeFinox BiotechHemoprostolLatudaLinepharmaMasivieraNerventraNovartisPTC TherapeuticsReasanzRegulationTakeda PharmaceuticalsTeva Pharmaceutical IndustriesTranslarna

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market

Report: Latuda has greatest commercial potential among new agents entering the bipolar drug market


Dainippon Sumitomo Pharma/Sunovion/Takeda Pharmaceutical’s atypical antipsychotic Latuda (lurasidone)…

Dainippon Sumitomo PharmaGlobalLatudaMarkets & MarketingNeurologicalPharmaceuticalTakeda Pharmaceuticals

Takeda gains first European approval for lurasidone


Japan's largest drugmaker Takeda Pharma (TYO: 4502) says it has been granted approval by Switzerland's…

Dainippon Sumitomo PharmaEuropeLatudalurasidoneNeurologicalPharmaceuticalRegulationTakeda Pharmaceuticals

US FDA backs news indications for Latuda; grants Priority Review for Perjeta


Sunovion Pharmaceuticals, a US subsidiary of Japan's Dainippon Sumitomo Pharma (TYO: 4506), says that…

BiotechnologyDainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaOncologyPerjetaPharmaceuticalRegulationRocheSunovion

Sunovion files two sNDAs for Latuda with FDA


Sunovion Pharmaceuticals, a US subsidiary of Japanese drug major Dainippon Sumitomo (TYO: 4506) has submitted…

Dainippon Sumitomo PharmaLatudaNeurologicalNorth AmericaPharmaceuticalRegulationSunovion

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression


Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two…

Dainippon Sumitomo PharmaLatudaNeurologicalPharmaceuticalResearch

Back to top